Sun Pharmaceutical Industries Ltd, the country’s largest drugmaker by revenue and market value, has slipped behind the Sensex and Nifty in 2025 — its first spell of underperformance in six years. The weakness reflects softer momentum in the US business, rising competition in generics, sustained pricing pressure at home and abroad, unfavorable currency movements across several emerging markets and continuing tariff uncertainty